EssilorLuxottica says Stellest 2.0 myopia lenses cut progression by 0.51D at six months in China trial

By Public Technologies
  • EssilorLuxottica reported interim six-month results from an ongoing randomized, double-blind clinical trial of Stellest 2.0 myopia-control lenses in China.
  • Findings were first presented at a scientific symposium held alongside the ESCRS meeting in London.
  • The lenses showed stronger myopia-control performance versus standard single-vision lenses, suggesting a faster treatment response.
  • High wear-time compliance was reported, with comfort and adaptation broadly comparable to conventional lenses.
  • The study continues, with the pre-specified one-year analysis set as the primary efficacy endpoint.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EssilorLuxottica SA published the original content used to generate this news brief on September 22, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.